Evercore ISI lowered the firm’s price target on BioCryst to $10 from $13 and keeps an Outperform rating on the shares following the firm’s quarterly HAE physician survey. The firm has removed BCX10013 from its model until it gets more visibility on its prospects and adds that it thinks BioCryst could be profitable in the 2027 timeframe in a scenario "focused just on Orladeyo."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BCRX:
- BioCryst to Report First Quarter 2023 Financial Results on May 3
- BioCryst announces $450M financing commitment from Pharmakon
- BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst reports inducement grants under Nasdaq listing rule